While nuclear PKM2 mediates EGFR-induced proliferation, epithelial-mesenchymal transition (EMT), migration and invasion in GBM, HCC and nasopharyngeal carcinoma cells [8,56,57,58], an EGFR-mediated nuclear function of PKM2 in lung cancer remains elusive despite a finding as a predictor for a response to PARP inhibitor treatment in EGFR-mutant NSCLC cells [44]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.